3653 results for «358»
3653 results
How to treat aortic regurgitation
22 May 2026 – From EuroPCR 2026
Explore cutting-edge transcatheter approaches for aortic regurgitation, including first-in-human ATLAS technique, management in LVAD patients, and off-label Myval use. This session reviews clinical challenges and innovative solutions in aortic valve interventions, offering valuable insights from complex procedural experiences.
Left main complications - Part 3
21 May 2026 – From EuroPCR 2026
This session reviews complex complications encountered in left main coronary interventions. It covers causes and management of acute left main occlusion, critical stenosis of coronary buttons, retrieval techniques for ostial stents, and strategies for managing challenging PCI scenarios that may precipitate or resolve catastrophic events.
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
Left main PCI: predictions of risk and long-term clinical outcome
22 May 2026 – From EuroPCR 2026
This session focuses on risk prediction and long-term outcomes following left main percutaneous coronary intervention (PCI). It covers biomarkers like NT-proBNP, hemodynamic predictors, and the impact of comorbidities such as diabetes and chronic kidney disease on patient prognosis over a ten-year follow-up.
Multivessel disease or left main disease
22 May 2026 – From EuroPCR 2026
This session explores revascularisation strategies for patients with multivessel or left main coronary artery disease. It emphasizes the role of intravascular physiology and imaging in guiding treatment decisions and highlights procedural factors that contribute to improved long-term clinical outcomes, supported by complex case discussions.
TAVI interventions for all? From congenital bicuspid valve towards valve-in-valve challenging cases
21 May 2026 – From EuroPCR 2026
This session delves into the complexities of TAVI interventions across diverse challenging cases, including congenital bicuspid valves and valve-in-valve scenarios. It emphasizes complication prevention, decision-making for the Unicorn technique, and the critical role of pre-procedural imaging, illustrated through detailed case studies from Estonia, the Netherlands, and...
When atrial septal closure gets complex
21 May 2026 – From EuroPCR 2026
This session explores the complexities that arise when atrial septal closure procedures become challenging. It covers hybrid retrieval techniques for occluder devices, management of device-related complications mimicking infection, resolution of uncommon complications, and case studies including cryptogenic stroke management in athletes, highlighting procedural intricacies and solutions.
STEMI management around the world
21 May 2026 – From EuroPCR 2026
This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
